Tumor budding as an indicator of prognosis in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis
Frontiers in Oncology · 09.04.2025 · 15
DOI: 10.3389/fonc.2025.1429319 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 09.04.2025. Verfasst von Azita Rafiee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Iranian Medical and Pathology Laboratory, Zahedan, Iran. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Tumor budding (TB) is recognized as a complementary prognostic factor for colorectal cancer. However, data on its impact on the survival of patients undergoing neoadjuvant chemoradiotherapy (nCRT) remain limited. This study aims to investigate the role of TB in disease-free survival (DFS) and overall survival (OS) among patients with locally advanced rectal cancer receiving nCRT.
Methods
In this systematic review and meta-analysis, an exhaustive search of the PubMed, Scopus, Web of Science (WOS), Embase, and Cochrane databases was conducted, ultimately leading to the extraction of eight studies in the qualitative assessment and meta-analysis.
Results
All the included studies were of high quality. The total sample size comprised 1,941 individuals. Although eight studies were included, nine datasets were extracted, as some studies reported multiple outcome measurements. TB positivity was statistically associated with decreased overall survival of 3.24 (95% confidence interval [CI]: 1.71–6.16) and disease-free survival of 2.54 (95% CI: 1.56–4.15) in patients with locally advanced rectal cancer undergoing nCRT.
Discussion
Based on the findings of this study, TB negativity was statistically and directly associated with better OS and DFS in patients with locally advanced rectal cancer undergoing nCRT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Iranian Medical and Pathology Laboratory, Zahedan, Iran.
- Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Pathology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Zitieren
APA
Rafiee, A., Nasri, P., Moradi, A., & Karimian, P. (2025). Tumor budding as an indicator of prognosis in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1429319
Vancouver
Rafiee A, Nasri P, Moradi A, Karimian P. Tumor budding as an indicator of prognosis in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1429319
BibTeX
@article{Rafiee2025,
author = {Rafiee, Azita and Nasri, Parto and Moradi, Afshin and Karimian, Paridokht},
title = {Tumor budding as an indicator of prognosis in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1429319}
}
EUVIMED